2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1089

Responsiveness of Physical Activity Measures Following Exercise Intervention in Individulas after Total Knee Arthroplasty
Abstract Number: 1090

Characteristics and Trajectories of Child Pain, Function, and Psychological Outcomes Associated with Conversion Disorder in Intensive Interdisciplinary Pediatric Pain Rehabilitation
Abstract Number: 1091

Effectiveness of Multidisciplinary Pain Rehabilitation Programs for Patients with Fibromyalgia Syndrome: A Systematic Review
Abstract Number: 1092

Illicit Drug Use in US Adults with Chronic Low Back Pain: Nhanes 2009-2010
Abstract Number: 1093

Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy
Abstract Number: 1094

Increased IgA Plasmablasts Are Associated with Rheumatoid Arthritis-Related Autoantibodies in the Absence of Inflammatory Arthritis
Abstract Number: 1095

Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis
Abstract Number: 1096

B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis
Abstract Number: 1097

Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis
Abstract Number: 1098

Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Abstract Number: 1099

Single Cell RNA-Seq Analysis of Citrullinated Alpha-Enolase Peptide-Specific B Cells in RA
Abstract Number: 1100

Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization
Abstract Number: 1101

Matrix Metalloproteinase-10 (Stromelysin 2) Is a Target of Robust Autoimmune T and B Cell Responses in Antibiotic-Refractory Lyme Arthritis, but Not in Rheumatoid Arthritis
Abstract Number: 1102

CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease
Abstract Number: 1103

Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion By Human Regulatory B Cells

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].